Hinge Health, Inc. Research and Development Expense
Hinge Health, Inc. (HNGE) reported Research and Development Expense of $34.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Hinge Health, Inc. research and development expense for the quarter ending 2026-06-30 was $34.06M, a 87.84% decline year-over-year.
- Hinge Health, Inc. research and development expense for the quarter ending 2026-03-31 was $30.34M, a 29.10% increase year-over-year.
- Hinge Health, Inc. research and development expense for the quarter ending 2025-12-31 was $32.76M, a 46.42% increase year-over-year.
- Hinge Health, Inc. research and development expense for the quarter ending 2025-09-30 was $31.92M, a 34.21% increase year-over-year.
- Hinge Health, Inc. research and development expense for fiscal 2025 was $368.14M, a 265.07% increase from fiscal 2024.
- Hinge Health, Inc. research and development expense for fiscal 2024 was $100.84M, a 8.38% decline from fiscal 2023.
- Hinge Health, Inc. research and development expense for fiscal 2023 was $110.06M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.06M 10-Q · filed 2026-08-06 | $64.39M 10-Q · filed 2026-08-06 | $97.15M derived: sum of 3 quarters · filed 2026-08-06 | $129.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $30.34M 10-Q · filed 2026-05-07 | $63.09M derived: sum of 2 quarters · filed 2026-05-07 | $95.01M derived: sum of 3 quarters · filed 2026-05-07 | $374.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $32.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $64.68M derived: sum of 2 quarters · filed 2026-03-03 | $344.64M derived: sum of 3 quarters · filed 2026-08-06 | $368.14M 10-K · filed 2026-03-03 |
| 2025-09-30 | $31.92M 10-Q · filed 2025-11-07 | $311.88M derived: sum of 2 quarters · filed 2026-08-06 | $335.38M 10-Q · filed 2025-11-07 | $357.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $279.96M 10-Q · filed 2026-08-06 | $303.46M 10-Q · filed 2026-08-06 | $325.83M derived: sum of 3 quarters · filed 2026-08-06 | $349.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $23.50M 10-Q · filed 2026-05-07 | $45.87M derived: sum of 2 quarters · filed 2026-05-07 | $69.66M derived: sum of 3 quarters · filed 2026-05-07 | $94.58M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $22.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $46.16M derived: sum of 2 quarters · filed 2026-03-03 | $71.08M derived: sum of 3 quarters · filed 2026-03-03 | $100.84M 10-K · filed 2026-03-03 |
| 2024-09-30 | $23.79M 10-Q · filed 2025-11-07 | $48.70M derived: sum of 2 quarters · filed 2025-11-07 | $78.47M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $24.92M 10-Q · filed 2025-08-11 | $54.68M 10-Q · filed 2025-08-11 | ||
| 2023-12-31 | $110.06M 10-K · filed 2026-03-03 |